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Summary A series of 46 primary bronchogenic carcinomas for which thymidine labelling index (% TLI) (in
all cases) and tumour doubling time (DTact) (in 13 cases) had previously been measured were followed up for
5 years and these data compared with length of post operative survival, tumour volume at operation and
pathological staging. We found no correlation between reduced survival and higher tumour % TLI, indeed the
reverse may be true. Larger tumours tended to have higher labelling indices considering either primary
tumour volume or 'T'-category. Five year survivors had smaller tumours, tended to have T1 tumours and
Stage I disease but did not have significantly lower tumour % TLIs. No relationship was found between
DTact and any other parameter.
A relationship between degree of malignancy and rate of
tumour growth is recognised for many malignancies (Charbit
et al., 1971). Various reports have described the' poorer
prognosis of rapidly growing pulmonary malignancies com-
pared with slowly growing lesions (Steele & Buell, 1973;
Meyer, 1973; Weiss et al., 1968). However the relationship
between tumour cell proliferation alone and prognosis is less
clear. Mitotic index, a crude measure of cell proliferation, is
roughly related to prognosis in many sarcomas (see Enzinger
& Weiss, 1983) but its value with regard to bronchogenic
carcinoma is more doubtful (Weiss, 1971). Aggressive
tumour types tend to have higher thymidine labelled indices
(% TLI) of their tumour cell populations (Malaise et al.,
1973) than less malignant lesions and % TLI has been shown
to be of some use as a prognostic indicator in carcinoma of
the breast (Meyer & Hixon, 1979). Recently interest in the
relationship between tumour cell proliferation and prognosis
has been rekindled with the prospect of studying tumours
using flow cytometry techniques (Friedlander et al., 1984).
We have already reported data on % TLI and actual
volume doubling times in a range of human pulmonary
neoplasms (Kerr et al., 1983; Kerr & Lamb, 1984). We have
followed up these patients, for at least 5 years and have
compared measurements of tumour size and growth kinetics
with postoperative survival.
Materials and methods
Case material
This study involved 46 patients who had thoracotomy and
pneumonectomy, lobectomy or segmentectomy with wedge
resection, combined with removal of all visible lymph nodes
found in the operative 'field', as the only treatment for their
pulmonary malignancy. All operations were performed by
the staff of the Thoracic Surgery Unit, City Hospital,
Edinburgh. All 46 patients had common histological types of
lung carcinoma (31 squamous carcinomas, 8 adeno-
carcinomas, 3 small cell carcinomas and 4 large cell un-
differentiated carcinomas).
Methods
The pathological material and reports were reviewed and the
tumours classified according to the interpretation used in
Edinburgh of the WHO classification of human broncho-
genic carcinomas (Lamb, 1984; 1987). When compared with
the classification as used previously (Kerr et al., 1983) the
major difference was that all the tumours regarded as 'large
cell with stratification' were reclassified as poorly differen-
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tiated squamous carcinomas. The volume of the primary
tumour was estimated from the maximum diameter of the
lesion after fixation assuming that the lesion was spherical.
The 'T' and 'N' category and stage of the tumours were
determined by the criteria laid down by the American
Thoracic Society (Tisi et al., 1983). 'T' category is deter-
mined principally by tumour size, T1 lesions being <3cm in
diameter and T2 lesions >3cm in diameter. Other criteria
are involved in classifying a tumour as T3 but our only case
was >3cm in diameter. No, N1, N2 refer to absent, hilar and
mediastinal lymph node metastases respectively. Tumour
stages I, II and III are derived from various combinations of
T and N status.
The % thymidine labelling index (% of S phase cells in
the tumour cell population) of all tumours was measured on
autoradiographs of paraffin-embedded tissue sections. S-
phase cells in small tumour fragments were labelled by
incubation at 370 C for 1 h in tissue culture medium contain-
ing 5pCiml-1 tritiated thymidine. Hyperbaric oxygenation
of the incubating tumour and medium was achieved by
injecting 6ml of 95% 02/5% CO2 into the 2ml air space of
the sealed bottles containing tumour fragments and culture
fluid. This technique together with the assessment of auto-
radiographs have been discussed in depth elsewhere (Kerr et
al., 1983).
Actual tumour volume doubling time (DTact) was mea-
sured on those cases where serial PA chest X-ray films
showing measurable tumours were available. DTact was
calculated as before (Kerr & Lamb, 1984) by Collins Graphi-
cal Method (Collins et al., 1956).
Details of death notifications were obtained from the
South East Scotland Cancer Registry, appropriate per-
mission having been obtained from the Lothian Health
Board. Information obtained on all cases included date of
registered death (as of March 31st, 1985), cause of death
registered on the death certificate and the address of the
patient's general practitioner. Where patients were from
outside Lothian Region, information was sought from the
relevant local Cancer Registry Office. Twenty-five of the 46
patients died of their tumour within five years of their
operation (non-survivors). Of these only 4 died at home and
had their deaths registered by their general practitioners; the
remaining 21 died in hospital. Thirteen patients survived
more than 5 years after their operation (survivors). Eight
patients died from causes other than their pulmonary malig-
nancy and within 5 years of operation so these patients' data
were excluded when survival was being considered.
Results
Table I represents the collated data on all 46 patients and
are grouped into non-survivors, survivors and those without
survival data. Some of these data on patients with both
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Table I Con
Hist 'T''N' ST
1 LCU 2 2
2 PDSQ 3 0
3 PDSQ 2 0
4 SCU 2 1
5 MDSQ 2 0
6 MDSQ 2 0
7 MDSQ 2 0
8 MDSQ 3 1
9 MDSQ 1 1
10 PDSQ 2 1
11 PDSQ 1 1
12 PDSQ 2 0
13 SCU 2 1
14 SCU 2 1
15 PDSQ 2 1
16 MDSQ 2 1
17 WDAD 2 0
18 PDSQ 2 1
19 MDSQ 2 0
20 MDAD 1 0
21 PDSQ 2 1
22 PDSQ 1 0
23 PDAD 1 0
24 PDAD 2 0
25 MDSQ 2 1
26 LCU 1 0
27 WDSQ 1 0
28 PDSQ 1 0
29 LCU 1 0
30 PDAD 2 0
31 PDSQ 1 1
32 LCU 1 1
33 PDSQ 2 1
34 WDSQ 1 1
35 WDSQ 1 0
36 PDSQ 2 1
37 PDSQ 2 0
38 PDSQ 1 0
39 WDAD 2 2
40 MDSQ 1 0
41 PDSQ 2 0
42 PDSQ 2 0
43 PDSQ 2 0
44 PDSQ 2 0
45 PDAD 2 1
46 WDAD 1 0
3
3
2
3
2
2
12
2
2
2
2
2
2
2
1
2
nposite data
D
% TLI
23.0
7.8
30.4
20.3
29.9
27.6
16.2
6.9
7.6
9.4
6.2
20.0
22.5
7.8
13.2
7.1
10.3
8.6
8.1
4.0
20.0
9.8
21.0
11.7
10.9
22.2
5.0
24.1
12.3
5.6
7.9
7.1
20.4
7.1
5.5
13.0
21.1
19.7
3.3
9.8
20.6
15.5
14.0
10.1
10.2
5.1
on all cases
)Tact Volume
days) (cm3)
154 180
- 14
- 113
24 65.4
- 268
33.5
8.2
- 65.4
95 14.0
55 33.5
94 22.4
- 113
65.4
- 33.5
23 47.6
20 113
- 33.5
- 14
- 268
- 14
- 180
185 4.2
- 4.2
14
- 14
58 33.5
- 14
- 14
93 87
- 8.2
- 14
- 33.5
- 65.4
37 33.5
- 65.4
8.2
- 33.5
22 33.5
- 113
- 65.4
98 33.5
- 8.2
Post-op
SURV
(days)
447
96
740
332
964
674
682
282
353
828
1064
270
485
60
295
255
701
176
245
936
406
245
166
234
186
>1825
>1825
> 1825
>1825
>1825
> 1825
>1825
> 1825
>1825
>1825
> 1825
>1825
>1825
Abbreviations used for histology (HIST) are as follows: LCU
(Large-Cell Undifferentiated); SCU (Small-Cell Undifferentiated);
SQ (Squamous Carcinoma); AD (Adenocarcinoma); PD, MD and
WD indicate poorly, moderately and well differentiated tumours
respectively. For each case the results where available are given for
'T' category*(T); 'N' category*(N) and Tumour Stage*(ST); % TLI;
DTact; Volume of primary tumours at resection (cm3) and Days
postoperative survival (POST-OP SURV).
*Classification adopted by American Thoracic Society (Tisi et al.,
1983).
% TLI and DTact measured on the same tumour have
already been published in detail (Kerr & Lamb, 1984). In
those patients who died of their tumour the mean post-
operative survival is 449 days (15 months) (456 days for
squamous and large cell carcinomas considered as a separate
group) and all died within 3 years of operation. Of the eight
cases excluded from the discussions on survival, because they
died within 5 years of operation of causes other than their
lung tumours, only one survived more than 3 years after
operation and none had an autopsy.
Thymidine labelling index and survival
The mean % TLI for the survivors (n = 13) is 11.7% and that
for non-survivors (n=25) is 14.4%. There is no significant
difference between these groups (Mann Whitney U test).
Figure 1 shows the relationship between % TLI and
postoperative survival for those who died of their tumour.
There is no correlation between reduced survival and
increased % TLI. However if squamous and large cell carci-
nomas are considered alone there is a trend suggesting that
survival is longer in those patients who had tumours with
higher % TLIs although this is not statistically significant
(P 0.05).
Actual doubling time and survival
The mean DTact in four patients surviving 5 years is 93 days
while that for seven non-survivors is 66 days. However this
difference is not statistically significant (Mann Whitney U
test) and there is no correlation between DTact and length
of postoperative survival in the non-survivors.
Tumour volume and survival
We have also examined the relationship between the volume
and postoperative prognosis. .The mean tumour volume
estimated on the formalin fixed surgically resected specimens
for the survivors (n=13) is 26cm3, (62% of these had a
volume of <15cm3), whereas for the non-survivors (n=21)
the mean volume was significantly greater at 81 cm3
(P=0.015, Mann Whitney U test). In those patients who
died of their tumour no correlation was found between
tumour volume at presentation and postoperative survival.
Tumour volume, thymidine labelling index and DTact
Larger tumours appear to have higher labelling indices than
smaller lesions. (r=0.44, 0.01 >P>0.001) (Figure 2). This
relationship is maintained within the squamous/large cell
carcinoma group (Figure 2 - all closed symbols). In the
group of non-survivors (Figure 2 - all round symbols)
%TLI and volume also correlated (r=0.43, 0.05>P>0.01).
No significant correlation between these two variables can be
found for the survivors (all square symbols). Tumour volume
at resection does not correlate with DTact (n = 13).
Pathological staging, thymidine labelling index and survival
Table II shows the number of cases segregated according to
'T' or 'N' category or tumour stage for survivors and non-
survivors. T3, N2 and Stage III cases are amalgamated with
T2, N1 and Stage II lesions respectively since the numbers
are so small (see Table I). For all T1 tumours (n= 16) the
mean tumour cell %TLI is 10.9% whereas for the T2/T3
lesions (n=30) it is significantly greater at 14.9% (P=0.019;
Mann Whitney U test). There is no significant difference in
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Figure 1 Each symbol represents one case. Closed symbols
represent squamous and large cell undifferentiated carcinomas;
open symbols small cell undifferentiated and adenocarcinomas.
For all cases there is no significant correlation. For squamous
and large cell carcinomas (closed symbols) r= +0.44 (P-0.05).
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Figure 2 Each symbol represents one case as follows.
Adeno & small cell Squamous & large cell
0 0
El U
A A
Non-survivors
Survivors
No survival date
For all cases r-= +0.44 (0.01 > P>0.001). A similar significant
correlation is seen for the group of squamous and large cell
carcinomas considered independently.
For non-survivors (all histological groups) r = +0.43
(0.05> P>0.01). No correlation can be found in the case of the
survivors.
Table II 'T', 'N' and overall stage classification of tumours in
survivors and non-survivors
T1 T213 No N112 Stage I Stages 11/111
Survivors 9 4 8 5 11 2
(n =13)
Non-survivors 5 20 12 13 13 12
(n =25)
% TI between the node positive and node negative cases or
between the early and later stage cases. There is a significant
d-iffterence in case distribution into 'T' category (P=0.003)
and overall tumour stage (P=0.048) between survivors and
non-survivors (Chi square test). Postoperative survival was
compared between each of the 'T' or 'N' categories and
tumour stage using the Mann Whitney U test. Survival is
significantly greater in patients with T1 tumours (P=0.004)
or Stage I disease (P=0.007) than for T2/73 tumours or
Stage 11/111 disease respectively. No significant difference in
survival was found between patients with and without lymph
node metastases found at operation.
Discussion
In our small and selected group of patients the overall 5 year
survival was 34%. This is similar to other series of resected
pulmonary tumours on which survival and tumour growth
and volume were compared (Steele et al., 1966; Jackman et
al., 1969). Those who died of their tumour all did so within
3 years of operation; a finding which supports the concept of
post-operative 5 year survival in lung cancer being synony-
mous with cure and agrees with the findings of Weiss
(1971a). This raises an important point relevant to the
remiaining discussion. Patients who survive 5 years and are
'6cured' (survivors) presumably have no metastatic disease at
the time of operation. Patients who die of malignancy at
some point after surgical resection of the primary tumour
are those who have metastases undetected at the time of
operation (or less likely have recurrent disease at the site of
incomplete resection). It would seem reasonable to assume
that, in these patients, the length of postoperative survival is
related to the biological behaviour of the tumour.
The similarity in mean % TLI between 'survivors' and
'non-survivors' in our study suggests that differences in
metastatic potential of tumour are not related to % TLI.
Meyer & Facher (1977) claimed that there was no relation-
ship in breast carcinoma between tumour % TLI and the
number of axillary node metastases. However, Meyer and
Hixon in 1979 reported that higher % TLI in breast carci-
noma was associated with increased axillary node metastasis
and that high % TLI could therefore predict an early relapse
in treated carcinoma of the breast. % TLI has also been
shown to be a prognostic indicator in a heterogeneous group
of gliomas (Hoshino & Wilson, 1979). Meyer himself con-
cedes, however, that, as with the brain tumours the correla-
tion of % TLI with prognosis in breast tumours may be
because the tumours studied were a mixture of different
types (Meyer, 1982). Meyer & Prioleau (1981) did not show
a relationship between % TLI and prognosis for a histo-
logically homogeneous group of colonic adenocarcinomas. In
our study high % TLI in those who died of their tumour was
not associated with reduced postoperative survival. The
squamous and large cell undifferentiated carcinoma in our
series allowed study of a relative homogenous. group of
cancers and showed a nearly significant trend of increased
postoperative survival with higher % TLI. We have already
shown that in human bronchogenic carcinoma increasing
% TLI is associated with increasing Cell Loss Factor in the
tumour (Kerr & Lamb, 1984). Cell Loss Factor may have an
influence in the survival of patients who have metastatic
disease at the time of operation. Cell death is as important
as cell production in determining the final growth rate of a
tumour and could therefore be expected to correlate with
prognosis. We know of no other study where % TLI has
been related to prognosis in human bronchogenic carcinoma
but Weiss (1971b) studied the effect of Mitotic Index on
survival and similarly found no correlation. It is interesting
that the biphasic distribution of data in our Figure 1
(Survival vs. % TLI) is similar to that of Weiss' plot of
Survival vs. MI. We have no explanation for this
distribution.
Steele & Buell (1973) suggested that tumour volume was
more important than its doubling time as a predictor of
surgical cure. Smaller tumours are easier to remove and are
less likely to be incompletely resected. Their suggestion also
implies that smaller tumours have a lower probability of
having metastasised at the time of operation. Larger
tumours, having probably progressed further along their
natural course than smaller lesions, have had more oppor-
tunity for cell dissemination. Wood et al. (1954) have
demonstrated this experimentally. There is abundant evi-
dence that smaller lesions do have a better prognosis (Jack-
man et al., 1969; Steele et a!., 1966) than larger lung tumours
and it is well established that an important prognostic
criterion in lung cancer is its stage (Lipford et al., 1984)
which in part depends on tumour size (Tisi et al., 1983). In
our series those cured by surgery had a much smaller mean
tumour volume than those who were not. Similarly there was
a greater tendency for survivors to have T1 lesions and Stage
I disease than the non-survivors. Tumour volume and posto-
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perative survival did not correlate in our series. This suggests
that any inadequate resections in our series were not con-
fined to the larger lesions and that primary tumour volume
does not necessarily relate to metastatic tumour load. Our
failure to demonstrate any prognostic significance for the
presence or absence of lymph node metastases was surpris-
ing. Lipford et al. (1984) clearly indicated that lymph node
mestastases were a bad prognostic factor in non small cell
carcinoma. Our case numbers are small and we do not
challenge the above authors' findings.
There are many reports showing that the growth rate or
actual doubling time of a tumour relates to its prognosis
(Weiss et al., 1966; Steele & Buell, 1973; Meyer, 1973; Weiss,
1974). Both Chahinian (1972) and Weiss (1971a) suggest that
more rapidly growing lung tumours are more likely to
metastasise and do so earlier in their natural history. This is
supported by experimental work (Martinez et al., 1956).
Thus differences in DTact might be expected between those
who do and do not live 5 years. Steele & Buell (1973) clearly
show that DTact does influence the length of postoperative
survival in those who have metastases at the time of
operation and who eventually die of their disease, as might
be expected. However, they also demonstrated that there was
no difference in DTact in those who were cured after lung
tumour resection and those who were not. Our results agree
with their latter finding but do not show a correlation
between DTact and postoperative survival. Our case
numbers are, however, small.
We have shown that smaller tumours have lower labelling
indices than larger lesions. In 1977 Meyer & Facher could
not demonstrate a relationship between breast carcinoma
size and % TLI but in 1979 Meyer & Hixon showed that
high % TLI was associated with larger size of primary breast
tumour. In experimental tumours there is evidence that
% TLI is either unchanged or decreased as a tumour gets
larger (Steel, 1977). This finding could reflect tumour pro-
gression over the course of its natural history. Over the
clinically observable period of a tumour's existence, most
evidence suggests that its growth rate is relatively constant
(Chahinian & Israel, 1976). Any tendency, during this period
for an increase in cell production must be mirrored by
increased cell loss from the tumour to maintain a constant
rate of net increase in cell numbers in the lesion. We have
already shown a close relationship between increasing thymi-
dine labelling index and increased cell loss factor in lung
tumours (Kerr & Lamb, 1984).
It is probable that no single factor, kinetic or otherwise, is
a principal determinant of prognosis in human bronchogenic
carcinoma (likelihood of cure or length of postoperative
survival) and that complex interrelationships of many differ-
ent factors are involved. We suggest, however, that % TLI is
not important as a prognostic indicator in human broncho-
genic carcinoma treated by surgery alone. This may also be
true in untreated cases but may not apply in cases of lung
cancer treated by other modalities.
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